Antriabio Announces Completion Of PK/PD Studies Of AB101
News Jan 09, 2015
AntriaBio, Inc. has successfully completed a series of in vitro and multi-species animal pharmacology studies for AB101, a potential once-weekly basal insulin being developed for patients with type 1 and type 2 diabetes. The studies assessed the receptor pharmacology, pharmacokinetics and pharmacodynamics of AB101 and support potential proof-of-concept for a once-weekly basal insulin in patients. The current standard of care in the $10 billion basal insulin market is a daily treatment.
"Despite the many advancements in therapy, there remain many challenges for patients with diabetes that may be mitigated by the availability of new, longer acting basal insulin therapy," said C. Ronald Kahn, M.D., Chief Academic Officer and Past President of Joslin Diabetes Center, the world's largest diabetes clinical care and research organization. "If successful in human clinical studies and commercialized, AB101 could reduce the number of required injections and may even help transition insulin-averse patients and providers to earlier use of insulin."
AntriaBio is currently engaged in additional studies, including ongoing toxicology studies that would support the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for AB101 and the subsequent launch of a clinical study in type 1 diabetes patients this year.
The Company's Vice President of Clinical Development, Brian Roberts, M.D., stated, "We are emboldened by the completion of these animal studies, which represents an exciting milestone toward advancing AB101 into clinical trials."
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
3-D Tissue Model of Developing Heart Could Aid Drug Safety Testing for Pregnant WomenNews
Parents and doctors often have to consider the mother's health as well as the potential risk regarding how medication could affect their baby. Researchers have developed a process to make a 3D tissue model that could mimic early stage human heart development, which could aid drug safety testing and help determine a drug's effects on fetal development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018